nodes	percent_of_prediction	percent_of_DWPC	metapath
Palonosetron—CYP1A2—Sorafenib—liver cancer	0.142	0.316	CbGbCtD
Palonosetron—CYP2D6—Sorafenib—liver cancer	0.117	0.26	CbGbCtD
Palonosetron—CYP3A4—Sorafenib—liver cancer	0.0743	0.166	CbGbCtD
Palonosetron—CYP2D6—Doxorubicin—liver cancer	0.0709	0.158	CbGbCtD
Palonosetron—CYP3A4—Doxorubicin—liver cancer	0.0451	0.1	CbGbCtD
Palonosetron—Peripheral sensory neuropathy—Sorafenib—liver cancer	0.0208	0.0522	CcSEcCtD
Palonosetron—Peripheral sensory neuropathy—Epirubicin—liver cancer	0.00768	0.0193	CcSEcCtD
Palonosetron—Myocardial ischaemia—Sorafenib—liver cancer	0.00739	0.0186	CcSEcCtD
Palonosetron—Peripheral sensory neuropathy—Doxorubicin—liver cancer	0.0071	0.0179	CcSEcCtD
Palonosetron—Hypocalcaemia—Sorafenib—liver cancer	0.00649	0.0163	CcSEcCtD
Palonosetron—Supraventricular extrasystoles—Epirubicin—liver cancer	0.00589	0.0148	CcSEcCtD
Palonosetron—Influenza like illness—Sorafenib—liver cancer	0.00577	0.0145	CcSEcCtD
Palonosetron—Supraventricular extrasystoles—Doxorubicin—liver cancer	0.00545	0.0137	CcSEcCtD
Palonosetron—Sinus tachycardia—Epirubicin—liver cancer	0.00545	0.0137	CcSEcCtD
Palonosetron—Sinus tachycardia—Doxorubicin—liver cancer	0.00504	0.0127	CcSEcCtD
Palonosetron—Pain in extremity—Sorafenib—liver cancer	0.00431	0.0108	CcSEcCtD
Palonosetron—Abdominal pain upper—Sorafenib—liver cancer	0.00394	0.00989	CcSEcCtD
Palonosetron—Hypokalaemia—Sorafenib—liver cancer	0.00392	0.00986	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.00388	0.00975	CcSEcCtD
Palonosetron—Gastritis—Sorafenib—liver cancer	0.00381	0.00959	CcSEcCtD
Palonosetron—Generalised oedema—Epirubicin—liver cancer	0.00369	0.00927	CcSEcCtD
Palonosetron—Generalised oedema—Doxorubicin—liver cancer	0.00341	0.00858	CcSEcCtD
Palonosetron—Hepatobiliary disease—Sorafenib—liver cancer	0.00314	0.0079	CcSEcCtD
Palonosetron—Epistaxis—Sorafenib—liver cancer	0.00313	0.00787	CcSEcCtD
Palonosetron—Dermatitis atopic—Epirubicin—liver cancer	0.00296	0.00745	CcSEcCtD
Palonosetron—Urinary tract disorder—Sorafenib—liver cancer	0.00294	0.0074	CcSEcCtD
Palonosetron—Connective tissue disorder—Sorafenib—liver cancer	0.00293	0.00736	CcSEcCtD
Palonosetron—Urethral disorder—Sorafenib—liver cancer	0.00292	0.00735	CcSEcCtD
Palonosetron—Amblyopia—Epirubicin—liver cancer	0.00284	0.00714	CcSEcCtD
Palonosetron—Feeling hot—Epirubicin—liver cancer	0.0028	0.00703	CcSEcCtD
Palonosetron—Tinnitus—Sorafenib—liver cancer	0.00278	0.00699	CcSEcCtD
Palonosetron—Cardiac disorder—Sorafenib—liver cancer	0.00277	0.00696	CcSEcCtD
Palonosetron—Dermatitis atopic—Doxorubicin—liver cancer	0.00274	0.00689	CcSEcCtD
Palonosetron—Glycosuria—Epirubicin—liver cancer	0.00271	0.00681	CcSEcCtD
Palonosetron—Angiopathy—Sorafenib—liver cancer	0.0027	0.0068	CcSEcCtD
Palonosetron—Immune system disorder—Sorafenib—liver cancer	0.00269	0.00677	CcSEcCtD
Palonosetron—Mediastinal disorder—Sorafenib—liver cancer	0.00269	0.00675	CcSEcCtD
Palonosetron—Arrhythmia—Sorafenib—liver cancer	0.00266	0.00669	CcSEcCtD
Palonosetron—Alopecia—Sorafenib—liver cancer	0.00263	0.00662	CcSEcCtD
Palonosetron—Amblyopia—Doxorubicin—liver cancer	0.00263	0.00661	CcSEcCtD
Palonosetron—Mental disorder—Sorafenib—liver cancer	0.00261	0.00657	CcSEcCtD
Palonosetron—Erythema—Sorafenib—liver cancer	0.0026	0.00652	CcSEcCtD
Palonosetron—Malnutrition—Sorafenib—liver cancer	0.0026	0.00652	CcSEcCtD
Palonosetron—Feeling hot—Doxorubicin—liver cancer	0.00259	0.0065	CcSEcCtD
Palonosetron—Dysgeusia—Sorafenib—liver cancer	0.00254	0.00639	CcSEcCtD
Palonosetron—Glycosuria—Doxorubicin—liver cancer	0.00251	0.0063	CcSEcCtD
Palonosetron—Ventricular extrasystoles—Epirubicin—liver cancer	0.00243	0.00611	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00241	0.00606	CcSEcCtD
Palonosetron—Anaemia—Sorafenib—liver cancer	0.0024	0.00603	CcSEcCtD
Palonosetron—Hypocalcaemia—Epirubicin—liver cancer	0.0024	0.00602	CcSEcCtD
Palonosetron—Dyskinesia—Epirubicin—liver cancer	0.00233	0.00587	CcSEcCtD
Palonosetron—Ventricular extrasystoles—Doxorubicin—liver cancer	0.00225	0.00565	CcSEcCtD
Palonosetron—Hypertension—Sorafenib—liver cancer	0.00224	0.00563	CcSEcCtD
Palonosetron—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.00223	0.00561	CcSEcCtD
Palonosetron—Hypocalcaemia—Doxorubicin—liver cancer	0.00222	0.00557	CcSEcCtD
Palonosetron—Myalgia—Sorafenib—liver cancer	0.00221	0.00555	CcSEcCtD
Palonosetron—Arthralgia—Sorafenib—liver cancer	0.00221	0.00555	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00219	0.00552	CcSEcCtD
Palonosetron—Hiccups—Epirubicin—liver cancer	0.00219	0.00552	CcSEcCtD
Palonosetron—Injection site reaction—Epirubicin—liver cancer	0.00218	0.00548	CcSEcCtD
Palonosetron—Dry mouth—Sorafenib—liver cancer	0.00216	0.00543	CcSEcCtD
Palonosetron—Dyskinesia—Doxorubicin—liver cancer	0.00216	0.00543	CcSEcCtD
Palonosetron—Hyperkalaemia—Epirubicin—liver cancer	0.00216	0.00542	CcSEcCtD
Palonosetron—Salivary hypersecretion—Epirubicin—liver cancer	0.00213	0.00536	CcSEcCtD
Palonosetron—Influenza like illness—Epirubicin—liver cancer	0.00213	0.00536	CcSEcCtD
Palonosetron—Anaphylactic shock—Sorafenib—liver cancer	0.00212	0.00532	CcSEcCtD
Palonosetron—Infection—Sorafenib—liver cancer	0.0021	0.00529	CcSEcCtD
Palonosetron—Shock—Sorafenib—liver cancer	0.00208	0.00524	CcSEcCtD
Palonosetron—Fluid retention—Epirubicin—liver cancer	0.00208	0.00524	CcSEcCtD
Palonosetron—Nervous system disorder—Sorafenib—liver cancer	0.00208	0.00522	CcSEcCtD
Palonosetron—Skin disorder—Sorafenib—liver cancer	0.00206	0.00517	CcSEcCtD
Palonosetron—Hiccups—Doxorubicin—liver cancer	0.00203	0.0051	CcSEcCtD
Palonosetron—Anorexia—Sorafenib—liver cancer	0.00202	0.00508	CcSEcCtD
Palonosetron—Injection site reaction—Doxorubicin—liver cancer	0.00202	0.00507	CcSEcCtD
Palonosetron—Hyperkalaemia—Doxorubicin—liver cancer	0.00199	0.00501	CcSEcCtD
Palonosetron—Salivary hypersecretion—Doxorubicin—liver cancer	0.00197	0.00496	CcSEcCtD
Palonosetron—Influenza like illness—Doxorubicin—liver cancer	0.00197	0.00496	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00193	0.00485	CcSEcCtD
Palonosetron—Fluid retention—Doxorubicin—liver cancer	0.00193	0.00484	CcSEcCtD
Palonosetron—Dyspnoea—Sorafenib—liver cancer	0.00189	0.00475	CcSEcCtD
Palonosetron—Dyspepsia—Sorafenib—liver cancer	0.00186	0.00469	CcSEcCtD
Palonosetron—Decreased appetite—Sorafenib—liver cancer	0.00184	0.00463	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Sorafenib—liver cancer	0.00183	0.0046	CcSEcCtD
Palonosetron—Fatigue—Sorafenib—liver cancer	0.00183	0.00459	CcSEcCtD
Palonosetron—Pain—Sorafenib—liver cancer	0.00181	0.00455	CcSEcCtD
Palonosetron—Constipation—Sorafenib—liver cancer	0.00181	0.00455	CcSEcCtD
Palonosetron—Gastrointestinal pain—Sorafenib—liver cancer	0.00173	0.00435	CcSEcCtD
Palonosetron—Hot flush—Epirubicin—liver cancer	0.0017	0.00428	CcSEcCtD
Palonosetron—Menopausal symptoms—Epirubicin—liver cancer	0.00169	0.00424	CcSEcCtD
Palonosetron—Body temperature increased—Sorafenib—liver cancer	0.00167	0.00421	CcSEcCtD
Palonosetron—Abdominal pain—Sorafenib—liver cancer	0.00167	0.00421	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Epirubicin—liver cancer	0.00165	0.00414	CcSEcCtD
Palonosetron—Pain in extremity—Epirubicin—liver cancer	0.00159	0.004	CcSEcCtD
Palonosetron—Hot flush—Doxorubicin—liver cancer	0.00158	0.00396	CcSEcCtD
Palonosetron—Menopausal symptoms—Doxorubicin—liver cancer	0.00156	0.00393	CcSEcCtD
Palonosetron—Hypersensitivity—Sorafenib—liver cancer	0.00156	0.00392	CcSEcCtD
Palonosetron—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00152	0.00383	CcSEcCtD
Palonosetron—Asthenia—Sorafenib—liver cancer	0.00152	0.00382	CcSEcCtD
Palonosetron—Pruritus—Sorafenib—liver cancer	0.0015	0.00377	CcSEcCtD
Palonosetron—Pain in extremity—Doxorubicin—liver cancer	0.00147	0.0037	CcSEcCtD
Palonosetron—Abdominal pain upper—Epirubicin—liver cancer	0.00145	0.00366	CcSEcCtD
Palonosetron—Hypokalaemia—Epirubicin—liver cancer	0.00145	0.00364	CcSEcCtD
Palonosetron—Diarrhoea—Sorafenib—liver cancer	0.00145	0.00364	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00143	0.00361	CcSEcCtD
Palonosetron—Gastritis—Epirubicin—liver cancer	0.00141	0.00354	CcSEcCtD
Palonosetron—Dizziness—Sorafenib—liver cancer	0.0014	0.00352	CcSEcCtD
Palonosetron—Abdominal distension—Epirubicin—liver cancer	0.00139	0.00348	CcSEcCtD
Palonosetron—Vomiting—Sorafenib—liver cancer	0.00135	0.00339	CcSEcCtD
Palonosetron—Abdominal pain upper—Doxorubicin—liver cancer	0.00135	0.00338	CcSEcCtD
Palonosetron—Hypokalaemia—Doxorubicin—liver cancer	0.00134	0.00337	CcSEcCtD
Palonosetron—Rash—Sorafenib—liver cancer	0.00134	0.00336	CcSEcCtD
Palonosetron—Dermatitis—Sorafenib—liver cancer	0.00133	0.00335	CcSEcCtD
Palonosetron—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00133	0.00334	CcSEcCtD
Palonosetron—Headache—Sorafenib—liver cancer	0.00133	0.00334	CcSEcCtD
Palonosetron—Gastritis—Doxorubicin—liver cancer	0.0013	0.00328	CcSEcCtD
Palonosetron—Abdominal distension—Doxorubicin—liver cancer	0.00128	0.00322	CcSEcCtD
Palonosetron—Nausea—Sorafenib—liver cancer	0.00126	0.00316	CcSEcCtD
Palonosetron—Hyperglycaemia—Epirubicin—liver cancer	0.00124	0.00312	CcSEcCtD
Palonosetron—Hepatobiliary disease—Epirubicin—liver cancer	0.00116	0.00292	CcSEcCtD
Palonosetron—Epistaxis—Epirubicin—liver cancer	0.00116	0.00291	CcSEcCtD
Palonosetron—Sinusitis—Epirubicin—liver cancer	0.00115	0.00289	CcSEcCtD
Palonosetron—Hyperglycaemia—Doxorubicin—liver cancer	0.00115	0.00289	CcSEcCtD
Palonosetron—Bradycardia—Epirubicin—liver cancer	0.00112	0.00282	CcSEcCtD
Palonosetron—Urinary tract disorder—Epirubicin—liver cancer	0.00109	0.00274	CcSEcCtD
Palonosetron—Connective tissue disorder—Epirubicin—liver cancer	0.00108	0.00272	CcSEcCtD
Palonosetron—Urethral disorder—Epirubicin—liver cancer	0.00108	0.00271	CcSEcCtD
Palonosetron—Hepatobiliary disease—Doxorubicin—liver cancer	0.00107	0.0027	CcSEcCtD
Palonosetron—Epistaxis—Doxorubicin—liver cancer	0.00107	0.00269	CcSEcCtD
Palonosetron—Sinusitis—Doxorubicin—liver cancer	0.00107	0.00268	CcSEcCtD
Palonosetron—Bradycardia—Doxorubicin—liver cancer	0.00104	0.00261	CcSEcCtD
Palonosetron—Eye disorder—Epirubicin—liver cancer	0.00103	0.00259	CcSEcCtD
Palonosetron—Tinnitus—Epirubicin—liver cancer	0.00103	0.00258	CcSEcCtD
Palonosetron—Cardiac disorder—Epirubicin—liver cancer	0.00102	0.00257	CcSEcCtD
Palonosetron—Urinary tract disorder—Doxorubicin—liver cancer	0.00101	0.00253	CcSEcCtD
Palonosetron—Connective tissue disorder—Doxorubicin—liver cancer	0.001	0.00252	CcSEcCtD
Palonosetron—Angiopathy—Epirubicin—liver cancer	0.001	0.00251	CcSEcCtD
Palonosetron—Urethral disorder—Doxorubicin—liver cancer	0.000999	0.00251	CcSEcCtD
Palonosetron—Immune system disorder—Epirubicin—liver cancer	0.000995	0.0025	CcSEcCtD
Palonosetron—Mediastinal disorder—Epirubicin—liver cancer	0.000993	0.0025	CcSEcCtD
Palonosetron—Chills—Epirubicin—liver cancer	0.000989	0.00249	CcSEcCtD
Palonosetron—Arrhythmia—Epirubicin—liver cancer	0.000984	0.00247	CcSEcCtD
Palonosetron—Alopecia—Epirubicin—liver cancer	0.000974	0.00245	CcSEcCtD
Palonosetron—Mental disorder—Epirubicin—liver cancer	0.000965	0.00243	CcSEcCtD
Palonosetron—Erythema—Epirubicin—liver cancer	0.000959	0.00241	CcSEcCtD
Palonosetron—Malnutrition—Epirubicin—liver cancer	0.000959	0.00241	CcSEcCtD
Palonosetron—Eye disorder—Doxorubicin—liver cancer	0.000953	0.00239	CcSEcCtD
Palonosetron—Tinnitus—Doxorubicin—liver cancer	0.000951	0.00239	CcSEcCtD
Palonosetron—Cardiac disorder—Doxorubicin—liver cancer	0.000946	0.00238	CcSEcCtD
Palonosetron—Flatulence—Epirubicin—liver cancer	0.000945	0.00238	CcSEcCtD
Palonosetron—Dysgeusia—Epirubicin—liver cancer	0.000939	0.00236	CcSEcCtD
Palonosetron—Angiopathy—Doxorubicin—liver cancer	0.000925	0.00233	CcSEcCtD
Palonosetron—Immune system disorder—Doxorubicin—liver cancer	0.000921	0.00231	CcSEcCtD
Palonosetron—Mediastinal disorder—Doxorubicin—liver cancer	0.000919	0.00231	CcSEcCtD
Palonosetron—Chills—Doxorubicin—liver cancer	0.000915	0.0023	CcSEcCtD
Palonosetron—Arrhythmia—Doxorubicin—liver cancer	0.000911	0.00229	CcSEcCtD
Palonosetron—Alopecia—Doxorubicin—liver cancer	0.000901	0.00226	CcSEcCtD
Palonosetron—Mental disorder—Doxorubicin—liver cancer	0.000893	0.00225	CcSEcCtD
Palonosetron—Malnutrition—Doxorubicin—liver cancer	0.000887	0.00223	CcSEcCtD
Palonosetron—Erythema—Doxorubicin—liver cancer	0.000887	0.00223	CcSEcCtD
Palonosetron—Anaemia—Epirubicin—liver cancer	0.000887	0.00223	CcSEcCtD
Palonosetron—Flatulence—Doxorubicin—liver cancer	0.000875	0.0022	CcSEcCtD
Palonosetron—Dysgeusia—Doxorubicin—liver cancer	0.000869	0.00218	CcSEcCtD
Palonosetron—Convulsion—Epirubicin—liver cancer	0.000831	0.00209	CcSEcCtD
Palonosetron—Hypertension—Epirubicin—liver cancer	0.000828	0.00208	CcSEcCtD
Palonosetron—Anaemia—Doxorubicin—liver cancer	0.00082	0.00206	CcSEcCtD
Palonosetron—Myalgia—Epirubicin—liver cancer	0.000817	0.00205	CcSEcCtD
Palonosetron—Arthralgia—Epirubicin—liver cancer	0.000817	0.00205	CcSEcCtD
Palonosetron—Anxiety—Epirubicin—liver cancer	0.000814	0.00205	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000811	0.00204	CcSEcCtD
Palonosetron—Discomfort—Epirubicin—liver cancer	0.000807	0.00203	CcSEcCtD
Palonosetron—Dry mouth—Epirubicin—liver cancer	0.000799	0.00201	CcSEcCtD
Palonosetron—Anaphylactic shock—Epirubicin—liver cancer	0.000783	0.00197	CcSEcCtD
Palonosetron—Infection—Epirubicin—liver cancer	0.000778	0.00195	CcSEcCtD
Palonosetron—Shock—Epirubicin—liver cancer	0.00077	0.00194	CcSEcCtD
Palonosetron—Convulsion—Doxorubicin—liver cancer	0.000769	0.00193	CcSEcCtD
Palonosetron—Nervous system disorder—Epirubicin—liver cancer	0.000768	0.00193	CcSEcCtD
Palonosetron—Hypertension—Doxorubicin—liver cancer	0.000766	0.00193	CcSEcCtD
Palonosetron—Tachycardia—Epirubicin—liver cancer	0.000764	0.00192	CcSEcCtD
Palonosetron—Skin disorder—Epirubicin—liver cancer	0.00076	0.00191	CcSEcCtD
Palonosetron—Myalgia—Doxorubicin—liver cancer	0.000756	0.0019	CcSEcCtD
Palonosetron—Arthralgia—Doxorubicin—liver cancer	0.000756	0.0019	CcSEcCtD
Palonosetron—Anxiety—Doxorubicin—liver cancer	0.000753	0.00189	CcSEcCtD
Palonosetron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00075	0.00189	CcSEcCtD
Palonosetron—Discomfort—Doxorubicin—liver cancer	0.000747	0.00188	CcSEcCtD
Palonosetron—Anorexia—Epirubicin—liver cancer	0.000746	0.00188	CcSEcCtD
Palonosetron—Dry mouth—Doxorubicin—liver cancer	0.000739	0.00186	CcSEcCtD
Palonosetron—Hypotension—Epirubicin—liver cancer	0.000731	0.00184	CcSEcCtD
Palonosetron—Anaphylactic shock—Doxorubicin—liver cancer	0.000724	0.00182	CcSEcCtD
Palonosetron—Infection—Doxorubicin—liver cancer	0.00072	0.00181	CcSEcCtD
Palonosetron—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000713	0.00179	CcSEcCtD
Palonosetron—Shock—Doxorubicin—liver cancer	0.000713	0.00179	CcSEcCtD
Palonosetron—Nervous system disorder—Doxorubicin—liver cancer	0.00071	0.00179	CcSEcCtD
Palonosetron—Insomnia—Epirubicin—liver cancer	0.000708	0.00178	CcSEcCtD
Palonosetron—Tachycardia—Doxorubicin—liver cancer	0.000707	0.00178	CcSEcCtD
Palonosetron—Skin disorder—Doxorubicin—liver cancer	0.000704	0.00177	CcSEcCtD
Palonosetron—Paraesthesia—Epirubicin—liver cancer	0.000703	0.00177	CcSEcCtD
Palonosetron—Dyspnoea—Epirubicin—liver cancer	0.000698	0.00175	CcSEcCtD
Palonosetron—Somnolence—Epirubicin—liver cancer	0.000696	0.00175	CcSEcCtD
Palonosetron—Anorexia—Doxorubicin—liver cancer	0.00069	0.00174	CcSEcCtD
Palonosetron—Dyspepsia—Epirubicin—liver cancer	0.000689	0.00173	CcSEcCtD
Palonosetron—Decreased appetite—Epirubicin—liver cancer	0.00068	0.00171	CcSEcCtD
Palonosetron—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.000678	0.00443	CbGpPWpGaD
Palonosetron—Hypotension—Doxorubicin—liver cancer	0.000677	0.0017	CcSEcCtD
Palonosetron—Gastrointestinal disorder—Epirubicin—liver cancer	0.000676	0.0017	CcSEcCtD
Palonosetron—Fatigue—Epirubicin—liver cancer	0.000675	0.0017	CcSEcCtD
Palonosetron—CYP1A2—Phase II conjugation—GSTA3—liver cancer	0.000675	0.00441	CbGpPWpGaD
Palonosetron—Pain—Epirubicin—liver cancer	0.000669	0.00168	CcSEcCtD
Palonosetron—Constipation—Epirubicin—liver cancer	0.000669	0.00168	CcSEcCtD
Palonosetron—CYP1A2—Estrogen Receptor Pathway—JUN—liver cancer	0.000665	0.00435	CbGpPWpGaD
Palonosetron—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00066	0.00166	CcSEcCtD
Palonosetron—Insomnia—Doxorubicin—liver cancer	0.000655	0.00165	CcSEcCtD
Palonosetron—CYP1A2—Melatonin metabolism and effects—CYP1A1—liver cancer	0.000653	0.00427	CbGpPWpGaD
Palonosetron—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.000652	0.00426	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—liver cancer	0.000651	0.00425	CbGpPWpGaD
Palonosetron—Paraesthesia—Doxorubicin—liver cancer	0.00065	0.00163	CcSEcCtD
Palonosetron—Dyspnoea—Doxorubicin—liver cancer	0.000646	0.00162	CcSEcCtD
Palonosetron—Somnolence—Doxorubicin—liver cancer	0.000644	0.00162	CcSEcCtD
Palonosetron—Gastrointestinal pain—Epirubicin—liver cancer	0.00064	0.00161	CcSEcCtD
Palonosetron—Dyspepsia—Doxorubicin—liver cancer	0.000638	0.0016	CcSEcCtD
Palonosetron—Decreased appetite—Doxorubicin—liver cancer	0.00063	0.00158	CcSEcCtD
Palonosetron—CYP1A2—Tryptophan metabolism—CYP2E1—liver cancer	0.000628	0.0041	CbGpPWpGaD
Palonosetron—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000625	0.00157	CcSEcCtD
Palonosetron—Fatigue—Doxorubicin—liver cancer	0.000624	0.00157	CcSEcCtD
Palonosetron—Pain—Doxorubicin—liver cancer	0.000619	0.00156	CcSEcCtD
Palonosetron—Constipation—Doxorubicin—liver cancer	0.000619	0.00156	CcSEcCtD
Palonosetron—Abdominal pain—Epirubicin—liver cancer	0.000619	0.00156	CcSEcCtD
Palonosetron—Body temperature increased—Epirubicin—liver cancer	0.000619	0.00156	CcSEcCtD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000617	0.00403	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTA4—liver cancer	0.000617	0.00403	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTA2—liver cancer	0.000601	0.00393	CbGpPWpGaD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000599	0.00392	CbGpPWpGaD
Palonosetron—Gastrointestinal pain—Doxorubicin—liver cancer	0.000592	0.00149	CcSEcCtD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000592	0.00387	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000583	0.00381	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTA1—liver cancer	0.00058	0.00379	CbGpPWpGaD
Palonosetron—Hypersensitivity—Epirubicin—liver cancer	0.000577	0.00145	CcSEcCtD
Palonosetron—CYP1A2—Estrogen Receptor Pathway—STAT3—liver cancer	0.000575	0.00376	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—NAT2—liver cancer	0.000574	0.00375	CbGpPWpGaD
Palonosetron—Body temperature increased—Doxorubicin—liver cancer	0.000573	0.00144	CcSEcCtD
Palonosetron—Abdominal pain—Doxorubicin—liver cancer	0.000573	0.00144	CcSEcCtD
Palonosetron—Asthenia—Epirubicin—liver cancer	0.000562	0.00141	CcSEcCtD
Palonosetron—Pruritus—Epirubicin—liver cancer	0.000554	0.00139	CcSEcCtD
Palonosetron—CYP1A2—Arachidonic acid metabolism—GGT1—liver cancer	0.000539	0.00353	CbGpPWpGaD
Palonosetron—HTR3A—Ion channel transport—RAF1—liver cancer	0.000537	0.00351	CbGpPWpGaD
Palonosetron—Diarrhoea—Epirubicin—liver cancer	0.000536	0.00135	CcSEcCtD
Palonosetron—Hypersensitivity—Doxorubicin—liver cancer	0.000534	0.00134	CcSEcCtD
Palonosetron—CYP3A4—Biological oxidations—UGDH—liver cancer	0.00053	0.00347	CbGpPWpGaD
Palonosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000526	0.00344	CbGpPWpGaD
Palonosetron—Asthenia—Doxorubicin—liver cancer	0.00052	0.00131	CcSEcCtD
Palonosetron—Dizziness—Epirubicin—liver cancer	0.000518	0.0013	CcSEcCtD
Palonosetron—Pruritus—Doxorubicin—liver cancer	0.000512	0.00129	CcSEcCtD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000508	0.00332	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000501	0.00328	CbGpPWpGaD
Palonosetron—Vomiting—Epirubicin—liver cancer	0.000498	0.00125	CcSEcCtD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—CASP3—liver cancer	0.000497	0.00325	CbGpPWpGaD
Palonosetron—Diarrhoea—Doxorubicin—liver cancer	0.000496	0.00125	CcSEcCtD
Palonosetron—Rash—Epirubicin—liver cancer	0.000494	0.00124	CcSEcCtD
Palonosetron—Dermatitis—Epirubicin—liver cancer	0.000493	0.00124	CcSEcCtD
Palonosetron—Headache—Epirubicin—liver cancer	0.00049	0.00123	CcSEcCtD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000486	0.00318	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000485	0.00317	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—JUN—liver cancer	0.000483	0.00316	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—CTNNB1—liver cancer	0.000479	0.00313	CbGpPWpGaD
Palonosetron—Dizziness—Doxorubicin—liver cancer	0.000479	0.0012	CcSEcCtD
Palonosetron—CYP2D6—Biological oxidations—NR1H4—liver cancer	0.000474	0.0031	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTA3—liver cancer	0.000466	0.00304	CbGpPWpGaD
Palonosetron—Nausea—Epirubicin—liver cancer	0.000465	0.00117	CcSEcCtD
Palonosetron—Vomiting—Doxorubicin—liver cancer	0.000461	0.00116	CcSEcCtD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTA3—liver cancer	0.000459	0.003	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—HPGDS—liver cancer	0.000459	0.003	CbGpPWpGaD
Palonosetron—Rash—Doxorubicin—liver cancer	0.000457	0.00115	CcSEcCtD
Palonosetron—Dermatitis—Doxorubicin—liver cancer	0.000456	0.00115	CcSEcCtD
Palonosetron—Headache—Doxorubicin—liver cancer	0.000454	0.00114	CcSEcCtD
Palonosetron—CYP1A2—Tryptophan metabolism—CYP1A1—liver cancer	0.000451	0.00295	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—liver cancer	0.000451	0.00295	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—liver cancer	0.000451	0.00295	CbGpPWpGaD
Palonosetron—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000434	0.00284	CbGpPWpGaD
Palonosetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000431	0.00281	CbGpPWpGaD
Palonosetron—Nausea—Doxorubicin—liver cancer	0.00043	0.00108	CcSEcCtD
Palonosetron—CYP2D6—Biological oxidations—GSTA4—liver cancer	0.000426	0.00278	CbGpPWpGaD
Palonosetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000425	0.00278	CbGpPWpGaD
Palonosetron—CYP1A2—Arachidonic acid metabolism—CYP1A1—liver cancer	0.000422	0.00276	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—liver cancer	0.000422	0.00276	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTA4—liver cancer	0.00042	0.00275	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTA2—liver cancer	0.000415	0.00271	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000412	0.00269	CbGpPWpGaD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000406	0.00265	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—NR1H4—liver cancer	0.000401	0.00262	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTA1—liver cancer	0.000401	0.00262	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—NAT2—liver cancer	0.000396	0.00259	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—CYCS—liver cancer	0.000396	0.00259	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTA3—liver cancer	0.000395	0.00258	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000392	0.00256	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—NAT2—liver cancer	0.000391	0.00255	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTA3—liver cancer	0.000389	0.00254	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000387	0.00253	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—liver cancer	0.000374	0.00244	CbGpPWpGaD
Palonosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000365	0.00238	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—TNF—liver cancer	0.000361	0.00236	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTA4—liver cancer	0.000361	0.00236	CbGpPWpGaD
Palonosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.00036	0.00235	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTA4—liver cancer	0.000356	0.00233	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTA2—liver cancer	0.000352	0.0023	CbGpPWpGaD
Palonosetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000349	0.00228	CbGpPWpGaD
Palonosetron—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000348	0.00228	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000344	0.00225	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GGT1—liver cancer	0.000343	0.00224	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTA1—liver cancer	0.000339	0.00222	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—NAT2—liver cancer	0.000336	0.00219	CbGpPWpGaD
Palonosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000335	0.00219	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GPX3—liver cancer	0.000332	0.00217	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—NAT2—liver cancer	0.000331	0.00216	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000318	0.00208	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—HPGDS—liver cancer	0.000317	0.00207	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.00031	0.00202	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTP1—liver cancer	0.000308	0.00201	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000305	0.00199	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.0003	0.00196	CbGpPWpGaD
Palonosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000296	0.00193	CbGpPWpGaD
Palonosetron—HTR3A—SIDS Susceptibility Pathways—IL6—liver cancer	0.000292	0.00191	CbGpPWpGaD
Palonosetron—CYP1A2—Phase II conjugation—GSTM1—liver cancer	0.000283	0.00185	CbGpPWpGaD
Palonosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000282	0.00184	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GPX3—liver cancer	0.000281	0.00184	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.000279	0.00182	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—PPARA—liver cancer	0.000278	0.00182	CbGpPWpGaD
Palonosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000278	0.00182	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—liver cancer	0.000277	0.00181	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000275	0.0018	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000271	0.00177	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—HPGDS—liver cancer	0.000268	0.00175	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000262	0.00171	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000259	0.00169	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP2E1—liver cancer	0.000258	0.00169	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000255	0.00167	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP2E1—liver cancer	0.000255	0.00166	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—liver cancer	0.000254	0.00166	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—liver cancer	0.000254	0.00166	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000249	0.00163	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000248	0.00162	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000242	0.00158	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GGT1—liver cancer	0.000237	0.00155	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000235	0.00153	CbGpPWpGaD
Palonosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000228	0.00149	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.000219	0.00143	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000217	0.00142	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.000216	0.00141	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTP1—liver cancer	0.000213	0.00139	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000211	0.00138	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	0.00021	0.00137	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000207	0.00135	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—ALB—liver cancer	0.000207	0.00135	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000201	0.00131	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—GSTM1—liver cancer	0.000196	0.00128	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000194	0.00127	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000194	0.00127	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	0.000193	0.00126	CbGpPWpGaD
Palonosetron—HTR3A—Transmembrane transport of small molecules—RAF1—liver cancer	0.000187	0.00122	CbGpPWpGaD
Palonosetron—CYP2D6—Biological oxidations—CYP1A1—liver cancer	0.000185	0.00121	CbGpPWpGaD
Palonosetron—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	0.000183	0.0012	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000181	0.00118	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000181	0.00118	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.00018	0.00118	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.00018	0.00117	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000178	0.00116	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000169	0.0011	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000166	0.00109	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.000166	0.00108	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000163	0.00107	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.00016	0.00104	CbGpPWpGaD
Palonosetron—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000157	0.00103	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000155	0.00101	CbGpPWpGaD
Palonosetron—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000155	0.00101	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000154	0.00101	CbGpPWpGaD
Palonosetron—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000153	0.000998	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.000139	0.00091	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—UGDH—liver cancer	0.000139	0.000906	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000137	0.000897	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—EPT1—liver cancer	0.00013	0.000852	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000128	0.000836	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000126	0.000824	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—TAT—liver cancer	0.000124	0.000808	CbGpPWpGaD
Palonosetron—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000121	0.000792	CbGpPWpGaD
Palonosetron—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.00012	0.000782	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000118	0.00077	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—UGDH—liver cancer	0.000117	0.000768	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—EPT1—liver cancer	0.00011	0.000722	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—TAT—liver cancer	0.000105	0.000684	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000103	0.000673	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—UGDH—liver cancer	9.07e-05	0.000593	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—EPT1—liver cancer	8.53e-05	0.000557	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CPT1B—liver cancer	8.4e-05	0.000549	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GLUL—liver cancer	8.4e-05	0.000549	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NR1H4—liver cancer	8.1e-05	0.00053	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—TAT—liver cancer	8.08e-05	0.000528	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA3—liver cancer	7.97e-05	0.000521	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	7.71e-05	0.000504	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA4—liver cancer	7.29e-05	0.000476	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CPT1B—liver cancer	7.12e-05	0.000465	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GLUL—liver cancer	7.12e-05	0.000465	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA2—liver cancer	7.1e-05	0.000464	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NR1H4—liver cancer	6.86e-05	0.000449	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTA1—liver cancer	6.85e-05	0.000448	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—NAT2—liver cancer	6.77e-05	0.000443	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA3—liver cancer	6.75e-05	0.000441	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALDOB—liver cancer	6.49e-05	0.000424	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CRABP1—liver cancer	6.19e-05	0.000405	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA4—liver cancer	6.17e-05	0.000403	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	6.03e-05	0.000394	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA2—liver cancer	6.01e-05	0.000393	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTA1—liver cancer	5.8e-05	0.000379	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—NAT2—liver cancer	5.74e-05	0.000375	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	5.52e-05	0.000361	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALDOB—liver cancer	5.5e-05	0.00036	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CPT1B—liver cancer	5.49e-05	0.000359	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GLUL—liver cancer	5.49e-05	0.000359	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HPGDS—liver cancer	5.41e-05	0.000354	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NR1H4—liver cancer	5.3e-05	0.000346	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CRABP1—liver cancer	5.25e-05	0.000343	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA3—liver cancer	5.21e-05	0.00034	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PSMD10—liver cancer	4.83e-05	0.000315	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PSMA4—liver cancer	4.83e-05	0.000315	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA4—liver cancer	4.76e-05	0.000311	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	4.73e-05	0.000309	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GOT2—liver cancer	4.69e-05	0.000307	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA2—liver cancer	4.64e-05	0.000303	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HPGDS—liver cancer	4.59e-05	0.0003	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	4.56e-05	0.000298	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTA1—liver cancer	4.48e-05	0.000293	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—NAT2—liver cancer	4.43e-05	0.000289	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP2E1—liver cancer	4.41e-05	0.000288	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALDOB—liver cancer	4.25e-05	0.000277	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	4.15e-05	0.000271	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYCS—liver cancer	4.13e-05	0.00027	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	4.1e-05	0.000268	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PSMD10—liver cancer	4.09e-05	0.000267	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PSMA4—liver cancer	4.09e-05	0.000267	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GGT1—liver cancer	4.05e-05	0.000265	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GOT1—liver cancer	4.05e-05	0.000265	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CRABP1—liver cancer	4.05e-05	0.000265	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GOT2—liver cancer	3.98e-05	0.00026	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP2E1—liver cancer	3.74e-05	0.000244	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTP1—liver cancer	3.64e-05	0.000238	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	3.62e-05	0.000237	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—HMOX1—liver cancer	3.59e-05	0.000235	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HPGDS—liver cancer	3.54e-05	0.000231	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYCS—liver cancer	3.5e-05	0.000229	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GGT1—liver cancer	3.43e-05	0.000224	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GOT1—liver cancer	3.43e-05	0.000224	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—GSTM1—liver cancer	3.35e-05	0.000219	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—CYP1A1—liver cancer	3.17e-05	0.000207	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PSMA4—liver cancer	3.16e-05	0.000206	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PSMD10—liver cancer	3.16e-05	0.000206	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTP1—liver cancer	3.08e-05	0.000202	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GOT2—liver cancer	3.07e-05	0.000201	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—HMOX1—liver cancer	3.04e-05	0.000199	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—MTHFR—liver cancer	2.96e-05	0.000193	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PPARA—liver cancer	2.9e-05	0.00019	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP2E1—liver cancer	2.89e-05	0.000189	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—GSTM1—liver cancer	2.83e-05	0.000185	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYCS—liver cancer	2.7e-05	0.000176	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—CYP1A1—liver cancer	2.69e-05	0.000176	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GOT1—liver cancer	2.65e-05	0.000173	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GGT1—liver cancer	2.65e-05	0.000173	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—MTHFR—liver cancer	2.5e-05	0.000164	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CG—liver cancer	2.48e-05	0.000162	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PPARA—liver cancer	2.46e-05	0.000161	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PPARG—liver cancer	2.4e-05	0.000157	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTP1—liver cancer	2.38e-05	0.000156	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—HMOX1—liver cancer	2.35e-05	0.000153	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.21e-05	0.000144	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—GSTM1—liver cancer	2.19e-05	0.000143	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CD—liver cancer	2.18e-05	0.000143	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—ALB—liver cancer	2.16e-05	0.000141	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CG—liver cancer	2.1e-05	0.000138	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—CYP1A1—liver cancer	2.07e-05	0.000136	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PPARG—liver cancer	2.03e-05	0.000133	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—MTHFR—liver cancer	1.93e-05	0.000126	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CB—liver cancer	1.9e-05	0.000124	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PPARA—liver cancer	1.9e-05	0.000124	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CD—liver cancer	1.85e-05	0.000121	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—ALB—liver cancer	1.83e-05	0.000119	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CG—liver cancer	1.62e-05	0.000106	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CB—liver cancer	1.61e-05	0.000105	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PPARG—liver cancer	1.57e-05	0.000102	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CD—liver cancer	1.43e-05	9.33e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—ALB—liver cancer	1.41e-05	9.21e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CB—liver cancer	1.24e-05	8.13e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—PIK3CA—liver cancer	1.16e-05	7.58e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—PIK3CA—liver cancer	9.83e-06	6.42e-05	CbGpPWpGaD
Palonosetron—CYP2D6—Metabolism—AKT1—liver cancer	9.48e-06	6.2e-05	CbGpPWpGaD
Palonosetron—CYP1A2—Metabolism—AKT1—liver cancer	8.03e-06	5.25e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—PIK3CA—liver cancer	7.59e-06	4.96e-05	CbGpPWpGaD
Palonosetron—CYP3A4—Metabolism—AKT1—liver cancer	6.2e-06	4.05e-05	CbGpPWpGaD
